DIMDNA
LIVE

Serial Number

99078272

Owner

SonoThera, Inc.

Attorney

Dustin Luettgen

Filing Date

Mar 11, 2025

Add to watchlist:

No watchlists yet
View on USPTO

DIMDNA Trademark

Serial Number: 99078272

DIMDNA is a trademark filed by SonoThera, Inc. on March 11, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

SonoThera, Inc. (7 trademarks)

201 Haskins Way
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

March 11, 2025

Registration Date

Not Registered

Published for Opposition

January 6, 2026

Goods & Services

Chemical preparations, enzymes and DNA for the preparation of nucleic acids for scientific and industrial purposes; chemicals for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; linear nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; single stranded nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; single and double-stranded nucleic acids for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; aptamers for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; enzymes for use in the preparation and creation of DNA extracts and cassettes for scientific and industrial purposes; DNA extracts and cassettes for scientific, industrial, and research use; DNA extracts being active chemical ingredients for use in the manufacture of therapeutics, biotechnology products and nanotechnology products; chemical preparations in the nature of DNA extracts for use in therapeutic, biotechnology and nanotechnology research

Pharmaceutical preparations for the diagnosis and treatment of human and veterinary genetics disease and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations for the prevention and treatment of genetic diseases; pharmaceutical preparations for human genetic medicines for treatment of genetic disease and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of nucleic acid sequences, DNA extracts, and chemical reagents for medical use for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; therapeutic nucleic acid preparations for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; nucleic acid preparations having aptamers for medical or veterinary purposes; pharmaceutical preparations consisting of single stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of single and double-stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of linear nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; pharmaceutical preparations consisting of single and double-stranded nucleic acids, DNA extracts and cassettes for treatment of genetic diseases and genetic diseases treatable with a nucleic acid therapy; nucleic acid sequences and chemical reagents for medical and veterinary purposes; nucleic acids comprising natural and unnatural nucleotides for medical and veterinary purposes; nucleic acid analogues comprising synthetic backbones or a mixture of natural and synthetic backbones for medical and veterinary purposes; composites of nucleic acids or nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in labeling, imaging and sensing applications; nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in smart materials; two-dimensional and three-dimensional nucleic acid analogues with organic and inorganic chemicals for medical and veterinary purposes in creating nanostructures and scaffolds

Scientific and technological services, namely, research and design in the field of nucleic acid research and development; chemical and biological analysis and research services; scientific research in the field of nucleic acids; scientific research and development in the field of creation of DNA extracts; scientific research, analysis, design and development relating to DNA based pharmaceutical drugs and therapies; scientific research and development in the fields of therapeutics, gene therapy, genetic medicines, diagnostics, biotechnology and nanotechnology; scientific research consultancy in the fields of therapeutics, gene therapy, genetic medicines, diagnostics, biotechnology, nanotechnology and DNA analysis

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 3, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 6, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jan 6, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 31, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 9, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 9, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 9, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 9, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 9, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 11, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 11, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 11, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 14, 2025 GNRN
NON-FINAL ACTION E-MAILED
Aug 14, 2025 GNRT
NON-FINAL ACTION WRITTEN
Aug 14, 2025 CNRT
ASSIGNED TO EXAMINER
Aug 12, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 11, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 11, 2025 NWOS
NEW APPLICATION ENTERED
Mar 11, 2025 NWAP